A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease
Completed
Teva Neuroscience, Inc.
Phase 4
2006-10-01
Patients with Parkinson's Disease (PD) will be divided into 2 groups at each study center at
their first visit based on the drugs they are taking for their PD:
- Group 1 Patients using Azilect and no other therapy.
- Group 2 Azilect in combination with other medications like Levodopa, Mirapex, or Requip.
The Effects of Rasagiline on Cognitive Deficits Associated With Parkinson's Disease
Unknown status
Istanbul University
Phase 4
2007-06-01
The objective of the study is to assess the effects of rasagiline on cognitive functions in
patient with Parkinson's disease. Patients on any dopaminergic medications will be assigned
to receive rasagiline 1 mg or placebo over 3 months. Cognitive functions will be assessed by
selected neuropsychological tests representing each cognitive domain.
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
Completed
H. Lundbeck A/S
2009-07-01
Eligible participants, who participated in the ADAGIO trial and who sign an approved informed
consent form, will be enrolled into the study at their original study locations. participants
who have stopped rasagiline therapy and in the opinion of the investigator will gain clinical
benefit from restarting treatment can also be considered for enrollment in the Core follow-up
study period. Use of any other anti-PD treatment is permitted as deemed necessary by the
treating physician (according to the participants clinical status).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
